A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-  Production in Vivo

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

(2011) Rong Deng et al.   mAbs

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

(2011) Y. J. Yu et al.   Science Translational Medicine

What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease?

(2010) Jeffrey Cummings   BIOLOGICAL PSYCHIATRY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

β-Secretase Inhibitor Potency Is Decreased by Aberrant β-Cleavage Location of the “Swedish Mutant” Amyloid Precursor Protein

(2009) Hidekuni Yamakawa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The  -Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential

(2009) R. Vassar et al.   JOURNAL OF NEUROSCIENCE

Amyloid Precursor Protein Trafficking, Processing, and Function

(2008) Gopal Thinakaran et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability†

(2008) Nicolas Charrier et al.   JOURNAL OF MEDICINAL CHEMISTRY

β-Secretase as a therapeutic target for Alzheimer’s disease

(2008) Arun K. Ghosh et al.   Neurotherapeutics

Efficient Inhibition of the Alzheimer's Disease  -Secretase by Membrane Targeting

(2008) L. Rajendran et al.   SCIENCE